Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Cited by (1,000)

Items 201–300 of 1,000

1. Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta‐analysis
   Suat Küçükgöncü, Urška Košir, Elton K. Zhou, Erin L. Sullivan, Vinod H. Srihari, Cenk Tek · 2018 · Early Intervention in Psychiatry
2. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
   Maarten Bak, Marjan Drukker, Shauna A M Cortenraad, Emma Vandenberk, Sinan Gülöksüz · 2021 · PLoS ONE
3. Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation
   Cooper, Ruth E., Hanratty, Éanna, Morant, Nicola, Moncrieff, Joanna · 2019 · PLoS ONE
4. Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials
   Jing Huang, Dongyu Kang, Fengyu Zhang, Ye Yang, Chenchen Liu, Jingmei Xiao, Yujun Long, Bing Lang, Xingjie Peng, Weiyan Wang et al. · 2022 · Schizophrenia Bulletin
5. Selective Activation of Cells by Piezoelectric Molybdenum Disulfide Nanosheets with Focused Ultrasound
   Ching‐Hsiang Fan, Hong‐Chieh Tsai, Yi-Sheng Tsai, Hsien‐Chu Wang, Yu‐Chun Lin, Po‐Han Chiang, Nan Wu, Min-Hwa Chou, Yi-Ju Ho, Zong‐Hong Lin et al. · 2023 · ACS Nano
6. Pharmacological interventions for prevention of weight gain in people with schizophrenia
   Sri Mahavir Agarwal, Nicolette Stogios, Zohra A Ahsan, Jonathan Lockwood, Markus J. Duncan, Hiroyoshi Takeuchi, Tony A. Cohn, Valerie H. Taylor, Gary J. Remington, Guy Faulkner et al. · 2022 · Cochrane Database of Systematic Reviews
7. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study
   Correll, Christoph U., Cucchiaro, Josephine, Silva, Robert, Hsu, Jay, Pikalov, Andrei, Loebel, Antony · 2016 · CNS Spectrums
8. Insulin-resistance in paediatric age: Its magnitude and implications
   Mohammed Al‐Beltagi, Adel Salah Bediwy, Nermin Kamal Saeed · 2022 · World Journal of Diabetes
9. Drug‐Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism
   Uchenna Anyanwagu, ISKANDAR RAUF IDRIS, Richard Donnelly · 2015 · Clinical Pharmacology & Therapeutics
10. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects
    Emil Joseph, Satish Reddi, Vibhu Rinwa, Garima Balwani, Ranendra Narayan Saha · 2017 · European Journal of Pharmaceutical Sciences
11. Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics
    Samantha Álvarez-Herrera, Raúl Iván Escamilla-Orozco, Oscar Medina Contreras, Ricardo Saracco, Yvonne Flores-Medina, Gabriela Hurtado‐Alvarado, José Luis Maldonado-García, Enrique Becerril‐Villanueva, Gilberto Pérez‐Sánchez, Lenin Pavón · 2020 · Frontiers in Endocrinology
12. Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders
    Pornpen Srisawasdi, Natchaya Vanwong, Yaowaluck Hongkaew, Apichaya Puangpetch, Somlak Vanavanan, Boontarika Intachak, Nattawat Ngamsamut, Penkhae Limsila, Chonlaphat Sukasem, Martin H. Kroll · 2017 · Clinical Biochemistry
13. DIABETIC KETOACIDOSIS ASSOCIATED WITH ANTIPSYCHOTIC DRUGS: CASE REPORTS AND A REVIEW OF LITERATURE
    Antonia Vuk, Martina Rojnić Kuzman, Maja Baretić, Martina Matovinović Osvatić · 2017 · Psychiatria Danubina
14. Increases in triglyceride levels are associated with clinical response to clozapine treatment
    John Lally, Anne Gallagher, Emma D. Bainbridge, G Avalos, Mohamed Rifaat Ahmed, Colm McDonald · 2013 · Journal of Psychopharmacology
15. Serving Persons With Severe Mental Illness in Primary Care–Based Medical Homes
    Domino, Marisa E., Wells, Rebecca, Morrissey, Joseph P. · 2015 · Psychiatric Services
16. Relative Risk of Acute Myocardial Infarction in People with Schizophrenia and Bipolar Disorder: A Population-Based Cohort Study
    Shu‐I Wu, Su‐Chiu Chen, Shen‐Ing Liu, Fang‐Ju Sun, Jyh‐Ming Jimmy Juang, Hsin‐Chien Lee, Kai‐Liang Kao, Michael E. Dewey, Martin James Prince, Robert J. Stewart · 2015 · PLoS ONE
17. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome
    Jorge Zimbron, Golam Mohammed Khandaker, Chiara Toschi, Peter Brian Jones, Emilio Fernández-Egea · 2016 · European Neuropsychopharmacology
18. Treating schizophrenia during menopause
    Amnon Brzezinski, Noa A. Brzezinski‐Sinai, Mary V. Seeman · 2016 · Menopause The Journal of The North American Menopause Society
19. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients
    Julia Lappin, Marlene Wijaya, Andrew Watkins, Rachel Morell, Scott B. Teasdale, Oscar Lederman, Simon Rosenbaum, Stephanie Dick, Philip B. Ward, Jackie Curtis · 2018 · Schizophrenia Research
20. Mortality, Revascularization, and Cardioprotective Pharmacotherapy After Acute Coronary Syndrome in Patients With Psychotic Disorders: A Population-Based Cohort Study
    Wing Chung Chang, Joe Kwun Nam Chan, Corine Sau Man Wong, JoJo S. H. Hai, Philip Chi Fai Or, Eric Yu Hai Chen · 2020 · Schizophrenia Bulletin
21. Automated design and optimization of multitarget schizophrenia drug candidates by deep learning
    Xiaoqin Tan, Xiangrui Jiang, He Yang, Feisheng Zhong, Xutong Li, Zhaoping Xiong, Zhaojun Li, Xiaohong Liu, Cui Chen, Qingjie Zhao et al. · 2020 · European Journal of Medicinal Chemistry
22. Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms
    Manter, Mariah A., Birtwell, Kirstin B., Bath, James, Friedman, Nora D. B., Keary, Christopher J., Neumeyer, Ann M., Palumbo, Michelle L., Thom, Robyn P., Stonestreet, Emily, Brooks, Hannah et al. · 2025 · BMC Medicine
23. Widespread white-matter microstructure integrity reduction in first-episode schizophrenia patients after acute antipsychotic treatment
    Linghui Meng, Kaiming Li, Wenbin Li, Yuan Xiao, Su Lui, John A. Sweeney, Qiyong Gong · 2018 · Schizophrenia Research
24. Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis
    Stefan Leucht, Andrea Cipriani, Loukia Maria Spineli, Dimitris Mavridis, Deniz Örey, Franziska Richter, Myrto T. Samara, Corrado Barbui, Rolf R. Engel, John Richard Geddes et al. · 2014 · FOCUS The Journal of Lifelong Learning in Psychiatry
25. Health‐related quality of life and aerobic fitness in people with schizophrenia
    Davy Vancampfort, Hannes Guelinckx, Michel Probst, Brendon Stubbs, Simon Rosenbaum, Philip B. Ward, Marc D. Binder · 2015 · International Journal of Mental Health Nursing
26. Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications
    Michael Leo Birnbaum, Ema Saito, Tobias Gerhard, Almut Gertrud Winterstein, Mark Olfson, John Michael Kane, Christoph Ulrich Correll · 2013 · Current Psychiatry Reports
27. Metabolic Syndrome in South African Patients with Severe Mental Illness: Prevalence and Associated Risk Factors
    Shamima Saloojee, Jonathan Kenneth Burns, Ayesha Ahmed Motala · 2016 · PLoS ONE
28. Understanding Engagement with a Physical Health Service: A Qualitative Study of Patients with Severe Mental Illness
    Osnat C. Melamed, Indira Fernando, Sophie Soklaridis, Margaret Hahn, Kirk W. LeMessurier, Valerie H. Taylor · 2019 · The Canadian Journal of Psychiatry
29. The chasm of care: Where does the mental health nursing responsibility lie for the physical health care of people with severe mental illness?
    D. Wynaden, Brett Heslop, Karen Heslop, L. Barr, Eric Lim, Gin-Liang Chee, James Porter, Jane Murdock · 2016 · International Journal of Mental Health Nursing
30. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study
    D. Bressington, J. Mui, Mei-Ling Tse, R. Gray, Eric F. C. Cheung, Wai-Tong Chien · 2016 · BMC Psychiatry
31. Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment
    Xu‐Feng Huang, Xueqin Song · 2018 · Medicinal Research Reviews
32. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia
    Emsley, Robin, Asmal, Laila, Rubio, Jose M., Correll, Christoph U., Kane, John M. · 2020 · Schizophrenia Research
33. Potential gains in life expectancy from reducing amenable mortality among people diagnosed with serious mental illness in the United Kingdom
    Dregan, Alex, McNeill, Ann, Gaughran, Fiona, Jones, Peter B., Bazley, Anna, Cross, Sean, Lillywhite, Kate, Armstrong, David, Smith, Shubulade, Osborn, David P. J. et al. · 2020 · PLOS ONE
34. CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity
    Liliang Li, Pan Gao, Xinru Tang, Zheng Liu, Mengying Cao, Ruoyu Luo, Xiaoqing Li, Jing Wang, Xinyi Lin, Chao Peng et al. · 2022 · Signal Transduction and Targeted Therapy
35. Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
    Shi Hyun Kang, Jong Il Lee · 2015 · Psychiatry Investigation
36. Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up
    Lene Nyboe, Claus Høstrup Vestergaard, Marianne Kleis Moeller, Hans Lund, Poul Videbech · 2015 · Schizophrenia Research
37. The Efficacy of Psychotherapy: Focus on Psychodynamic Psychotherapy as an Example
    Kenneth N. Levy, Johannes C. Ehrenthal, Frank E. Yeomans, Eve Caligor · 2014 · Psychodynamic Psychiatry
38. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials
    Britta Galling, Alexandra Roldán, Liz Rietschel, Katsuhiko Hagi, Frozan Walyzada, Wei Zheng, Xiao‐Lan Cao, Yu‐Tao Xiang, John Michael Kane, Christoph U. Correll · 2016 · Expert Opinion on Drug Safety
39. Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis
    Priyanthi Borgen Gjerde, Ingrid Dieset, Carmen Simonsen, Eva Z. Hoseth, Trude Iversen, Trine Vik Lagerberg, Siv Hege Lyngstad, Ragni Helene Mørch, Silje Skrede, Ole A. Andreassen et al. · 2017 · Schizophrenia Research
40. Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia
    David E. Kemp, Christoph Ulrich Correll, Mauricio F. Tohen, Melissa P. DelBello, Stephen J. Ganocy, Robert L. Findling, Kiki Chang · 2013 · Journal of Child and Adolescent Psychopharmacology
41. The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors
    Rosa Shapiro-Thompson, Sarah Kathryn Fineberg · 2022 · Current Treatment Options in Psychiatry
42. Non-adherence to pharmacological treatment in schizophrenia and schizophrenia spectrum disorders – An updated systematic literature review
    Pernille S. Ljungdalh · 2017 · The European Journal of Psychiatry
43. Treating depressive episodes or symptoms in patients with schizophrenia
    Geeske van Rooijen, Jentien M. Vermeulen, Henricus Gerardus Ruhé, Lieuwe de Haan · 2017 · CNS Spectrums
44. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis
    Javier Vázquez-Bourgón, Rocío Pérez‐Iglesias, Víctor Ortiz‐García de la Foz, Paula Suarez Pinilla, Álvaro Díaz, Benedicto Crespo‐Facorro · 2017 · Psychopharmacology
45. Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review
    Marius H. Sneller, Nini de Boer, Sophie Everaars, Max Schuurmans, Sinan Gülöksüz, Wiepke Cahn, Jurjen Justin Luykx · 2021 · Frontiers in Psychiatry
46. Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?
    C. Correll, L. Sikich, G. Reeves, M. Riddle · 2013 · American Journal of Psychiatry
47. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis
    Narong Maneeton, Benchalak Maneeton, Suwannee Putthisri, Sirijit Suttajit, Surinporn Likhitsathian, Manit Srisurapanont · 2018 · Neuropsychiatric Disease and Treatment
48. Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs
    Georgia Dorahy, Zheng Chen, Thomas Balle · 2023 · Molecules
49. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)
    Marie Reeberg Sass, Andreas Aalkjær Danielsen, Ole Köhler‐Forsberg, Heidi Storgaard, Filip Krag Knop, Mette Ødegaard Nielsen, Anders Mikael Sjödin, Ole N Mors, Christoph Ulrich Correll, Claus Thorn Ekstrøm et al. · 2023 · BMJ Open
50. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis
    Rocío Pérez‐Iglesias, Víctor Ortiz‐García de la Foz, Obdulia Martínez‐García, José Amado, María Teresa García‐Unzueta, Rosa Ayesa‐Arriola, Paula Suárez‐Pinilla, Rafael Tabarés‐Seisdedos, Benedicto Crespo‐Facorro · 2014 · Schizophrenia Research
51. Mortality risk in a nationwide cohort of individuals with tic disorders and with tourette syndrome
    Sandra Melanie Meier, Søren Dalsgaard, Preben Bo Mortensen, James Frederick Leckman, Kerstin Jessica Plessen · 2017 · Movement Disorders
52. Effects of psychopharmacological treatment with antipsychotic drugs on the vascular system
    Kai G. Kahl, Mechthild Westhoff‐Bleck, Tillmann H. C. Krüger · 2017 · Vascular Pharmacology
53. Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale
    Theodora A. Manolis, Antonis S. Manolis, Antonis S. Manolis · 2018 · Angiology
54. Network pharmacology-based identification for therapeutic mechanism of Ling-Gui-Zhu-Gan decoction in the metabolic syndrome induced by antipsychotic drugs
    Si-Ying Xiang, Jing Zhao, Ying Lu, Ru-Meng Chen, Yan Wang, Yi Chen, Bin Long, Li-Ping Zhu, Pei-Fen Yao, Yi-Feng Xu et al. · 2019 · Comput. Biol. Medicine
55. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism
    Ann A. Verhaegen, Luc F. Van Gaal · 2019 · Europe PMC (PubMed Central)
56. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
    Huhn, Maximilian, Leucht, Claudia, Rothe, Philipp, Dold, Markus, Heres, Stephan, Bornschein, Susanne, Schneider-Axmann, Thomas, Hasan, Alkomiet, Leucht, Stefan · 2021 · European Archives of Psychiatry and Clinical Neuroscience
57. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia
    Gretchen L. Snyder, Kimberly E. Vanover, Robert E. Davis, Peng Li, Allen A. Fienberg, Sharon L. Mates · 2020 · Advances in pharmacology
58. Psychological and Psychopharmacological Interventions in Psychocardiology
    Kai G. Kahl, Britta Stapel, Christoph Ulrich Correll · 2022 · Frontiers in Psychiatry
59. Cardiovascular risk factors and 30-year cardiovascular risk in homeless adults with mental illness
    Agnes Gozdzik, Roxana Salehi, Patricia J O'Campo, Vicky Stergiopoulos, Stephen W. Hwang · 2015 · BMC Public Health
60. Lurasidone in the treatment of schizophrenia: Results of a double‐blind, placebo‐controlled trial in Asian patients
    Teruhiko Higuchi, Jun Ishigooka, Masaomi Iyo, Chin‐Bin Yeh, Esther Gunaseli M. Ebenezer, Kuei Yu Liang, Jung Sik Lee, Sang-Yeol Lee, Shih‐Ku Lin, Bo-Hyun Yoon et al. · 2019 · Asia-Pacific Psychiatry
61. Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics
    Marsha A. Raebel, Robert B. Penfold, Ann W. McMahon, Marsha E. Reichman, Susan M. Shetterly, Glenn K. Goodrich, S. Andrade, Christoph Ulrich Correll, Tobias Gerhard · 2014 · PEDIATRICS
62. Transcriptome analysis of human induced excitatory neurons supports a strong effect of clozapine on cholesterol biosynthesis
    Debamitra Das, Xi Peng, Anh-Thu N. Lam, Joel S. Bader, Dimitrios Avramopoulos · 2021 · Schizophrenia Research
63. Patterns of psychotropic prescribing and polypharmacy in older hospitalized patients in Ireland: the influence of dementia on prescribing
    Kieran Anthony Walsh, Niamh O’Regan, Stephen Byrne, John Patrick Browne, David James Meagher, Suzanne Timmons · 2016 · International Psychogeriatrics
64. Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia
    Susan F. Sonnenschein, Anthony A. Grace · 2019 · Neuropharmacology
65. Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis
    Yewei Wang, Dandan Wang, Jie Cheng, Xinyu Fang, Yan Chen, Lingfang Yu, Juanjuan Ren, Yuan Tian, Chen Zhang · 2021 · Journal of Psychopharmacology
66. Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest
    Peter Ejvin Weeke, Aksel Karl Georg Jensen, Fredrik Folke, Gunnar Gislason, Jonas Bjerring Olesen, Emil Loldrup Fosbøl, Mads Wissenberg, Freddy Knudsen Lippert, Erika Frischknecht Christensen, Søren Loumann Nielsen et al. · 2014 · Clinical Pharmacology & Therapeutics
67. Gene‐specific DNA methylation may mediate atypical antipsychotic‐induced insulin resistance
    Kyle Jon Burghardt, Jaclyn M. Goodrich, Dana C. Dolinoy, Vicki L. Ellingrod · 2016 · Bipolar Disorders
68. Do antipsychotics increase diabetes risk in children and adolescents?
    Britta Galling, Christoph Ulrich Correll · 2014 · Expert Opinion on Drug Safety
69. Directions for Future Patient-Centered and Comparative Effectiveness Research for People With Serious Mental Illness
    The University of North Carolina at Chapel Hill University Libraries · 2014 · Schizophrenia Bulletin
70. Expanding Transdermal Delivery with Lipid Nanoparticles: A New Drug-in-NLC-in-Adhesive Design
    Maria Mendes, Sandra C. C. Nunes, João Sousa, Alberto A. C. C. Pais, Carla Vitorino · 2017 · Molecular Pharmaceutics
71. Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder
    Martin Strassnig, Danielle Cornacchio, Philip D. Harvey, Roman Kotov, Laura J. Fochtmann, Evelyn J. Bromet · 2017 · Journal of Psychiatric Research
72. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
    Stephen R. Marder, Mika Hakala, Mette Krog Josiassen, Peter G. Y. Zhang, John Ouyang, Emmanuelle Weiller, Catherine Weiss, Mary Hobart · 2016 · Acta Neuropsychiatrica
73. Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study
    Jung Sun Lee, Jun Soo Kwon, Daeho Kim, Sung‐Wan Kim, Jae‐Jin Kim, Jong‐Hoon Kim, Hee Jung Nam, Seunghyong Ryu, Il Ho Park, Suk Kyoon An et al. · 2017 · Psychiatry Investigation
74. Long‐term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52‐week, open‐label study
    Ishigooka, Jun, Iwashita, Shuichi, Tadori, Yoshihiro · 2018 · Psychiatry and Clinical Neurosciences
75. Diabetes, physical activity participation and exercise capacity in patients with schizophrenia
    Vancampfort, Davy, De Hert, Marc, Sweers, Kim, De Herdt, Amber, Detraux, Johan, Probst, Michel · 2013 · Psychiatry and Clinical Neurosciences
76. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
    Ebdrup, Bjørn H, Knop, Filip K, Ishøy, Pelle L, Rostrup, Egill, Fagerlund, Birgitte, Lublin, Henrik, Glenthøj, Birte · 2012 · BMC Medicine
77. All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
    Clàudia Aymerich, Gonzalo Salazar de Pablo, Malein Pacho, Violeta Pérez-Rodríguez, Amaia Bilbao, Lucía Gallego Andrés, Borja Pedruzo, Idoia Castillo-Sintes, Nerea Aranguren, Paolo Fusar‐Poli et al. · 2024 · Molecular Psychiatry
78. Improving physical health and reducing substance use in psychosis – randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial
    Fiona Gaughran, Daniel R. Stahl, Khalida Ismail, Zerrin Atakan, John Lally, Poonam Gardner-Sood, Anita K. Patel, Anthony S. David, David Hopkins, Bee Harries et al. · 2013 · BMC Psychiatry
79. Effects of olanzapine on the elevation of macrophage infiltration and pro-inflammatory cytokine expression in female rats
    Qingsheng Zhang, Meng Xiao He, Chao Deng, Hongqin Wang, Xu‐Feng Huang · 2014 · Journal of Psychopharmacology
80. Molecular Regulatory Pathways Link Sepsis With Metabolic Syndrome: Non-coding RNA Elements Underlying the Sepsis/Metabolic Cross-Talk
    Chanan Meydan, Uriya Bekenstein, Hermona Soreq · 2018 · Frontiers in Molecular Neuroscience
81. Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo
    Jacob S. Ballon, Utpal B. Pajvani, Laurel Mayer, Zachary Freyberg, Robin J. Freyberg, Ignacio Contreras, MICHAEL S. ROSENBAUM, Rudolph L. Leibel, Jeffrey Alan Lieberman · 2018 · Journal of Psychopharmacology
82. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
    Jacobi I. Cunningham, David J. Eyerman, Mark S. Todtenkopf, Reginald L. Dean, Daniel R. Deaver, Connie Sánchez, Mark Namchuk · 2019 · Journal of Psychopharmacology
83. The Association between Lifestyle Choices and Schizophrenia Symptoms
    Sylwia Kalinowska, Beata Trześniowska-Drukała, Karolina Kłoda, Krzysztof Safranow, Błażej Misiak, Agnieszka Cyran, Jerzy Samochowiec · 2021 · Journal of Clinical Medicine
84. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
    Christoph Ulrich Correll, Kimberly E. Vanover, Robert E. Davis, Richard Chen, Andrew Satlin, Sharon L. Mates · 2021 · Schizophrenia Research
85. The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain
    Trehani M. Fonseka, Arun Kumar Tiwari, Vanessa Faria Gonçalves, Jeffrey Alan Lieberman, Herbert Y. Meltzer, Benjamin I. Goldstein, James L. Kennedy, Sidney H. Kennedy, Daniel J. Müller · 2015 · The World Journal of Biological Psychiatry
86. Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs
    Julia M. Gohlke · 2012 · Frontiers in Psychiatry
87. Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study
    Yirgalem Shewakena Wubeshet, Oumer Sada Muhammed, Tigestu Alemu Desse · 2019 · BMC Psychiatry
88. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
    Yamin Shu, Yiling Ding, Lulu Liu, Qilin Zhang · 2023 · CNS Neuroscience & Therapeutics
89. Medication-induced hyperglycemia and diabetes mellitus: a review of current literature and practical management strategies
    Jain, Akshay B., Lai, Valerie · 2024 · Diabetes Therapy
90. Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats
    Kateřina Horská, Jana Kučerová, Zuzana Babinská, Michal Karpíšek, Regina Demlová, Radka Opatřilová, Pavel Suchý, Hana Kotolová · 2016 · Psychoneuroendocrinology
91. Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study
    Mikkel Højlund, Lars Christian Lund, Jonas Leander Emming Herping, Maija Bruun Haastrup, Per Damkier, Daniel Pilsgaard Henriksen · 2020 · BMJ Open
92. Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
    Marco Solmi, Alessandro Miola, Federico Capone, Simone Pallottino, Mikkel Højlund, Joseph Firth, Dan J. Siskind, Richard I. G. Holt, Olivier Corbeil, Samuele Cortese et al. · 2024 · Expert Opinion on Drug Safety
93. Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach
    Matisyahu Shulman, Avraham Miller, Jason Misher, Aleksey Tentler · 2014 · Journal of Multidisciplinary Healthcare
94. Detecting and Managing Adverse Effects of Antipsychotic Medications
    Donna Ames, Sian M. Carr‐Lopez, Mary A. Gutierrez, Joseph M. Pierre, Jennifer A. Rosen, Susan Shakib, Lynn M. Yudofsky · 2016 · Psychiatric Clinics of North America
95. Differences in Medicaid Antipsychotic Medication Measures Among Children with SSI, Foster Care, and Income-Based Aid
    Emily Leckman‐Westin, Molly T. Finnerty, Sarah Hudson Scholle, Riti Pritam, Deborah M. Layman, Edith M. Kealey, Sepheen C. Byron, Emily Morden, Scott M. Bilder, Sheree Neese‐Todd et al. · 2018 · Journal of Managed Care & Specialty Pharmacy
96. Impact of Environmental Modifications to Enhance Day-Night Orientation on Behavior of Nursing Home Residents With Dementia
    Thierry Bautrant, Michel Grino, Corinne Peloso, Frédéric Schiettecatte, Magali Planelles, Charles Oliver, Caroline Franqui · 2018 · Journal of the American Medical Directors Association
97. High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine
    Julie Rask Larsen, Camilla Kara Svensson, Louise Vedtofte, Mathilde S. L. Jakobsen, Hans Søe Riis Jespersen, Michelle Iris Jakobsen, Kamuran Koyuncu, Ole Schjerning, Jimmi Nielsen, Claus Thorn Ekstrøm et al. · 2018 · CNS Spectrums
98. Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: Involvement of the INSIG/SREBP pathway
    Ruili Dang, Pei Jiang, Hualin Cai, LI Huan-de, Ren Guo, Yanqin Wu, Lihong Zhang, Wen-Ye Zhu, Xin He, Yiping Liu et al. · 2015 · European Neuropsychopharmacology
99. Antipsychotic switching in bipolar disorders: a systematic review
    Iría Grande, Miquel Bernardo, Julio Bobes, Jerónimo Sáiz-Ruiz, Cecilio Álamo, Eduard Vieta · 2013 · The International Journal of Neuropsychopharmacology
100. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia
     Saana Eskelinen, Eila S. Sailas, Kaisla Joutsenniemi, Matti Mikael Holi, Jaana Suvisaari · 2015 · Nordic Journal of Psychiatry